Jump to content

Latest News

Thursday 7 September 2017
Press Releases

Marriott Harrison LLP advises Destiny Pharma Plc in relation to regulatory and IP issues in connection with its IPO and admission to trading on AIM

Life Sciences and IP partner Alex Denoon advised Destiny Pharma Plc in relation to regulatory and IP issues in connection with its IPO and admission to trading on AIM. The company, whose nominated adviser and broker is Cantor Fitzgerald & Co, raised a total of £15.3M on a post money valuation of £65m. The Company is dedicated to the discovery, development and commercialisation of novel antimicrobials to improve outcomes for patients and the delivery of medical care into the future.

Life Sciences

Recent News

Publications

Events

What Others Say


Design New Graphic